SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update

Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev ar

CRDF

Related stories